Bioventus Inc.

Bioventus Inc.

BVSยทNASDAQ

$8.55

+5.4%
HealthcareMedical - Devices

Bioventus Inc. a medical device company, focuses on developing and commercializing clinical treatments that engage and enhance the body's natural healing process in the United States and internationally. The company's product portfolio includes pain treatments, which comprise non-surgical joint pain injection therapies, as well as peripheral nerve stimulation products. Its surgical solutions comprise bone graft substitutes to fuse and grow bones, enhance results following spinal and other orthopedic surgeries; and ultrasonic medical devices for the use in precise bone sculpting, remove tumors, and tissue debridement. The company's restorative therapies include an ultrasonic bone healing system for fracture care; skin allografts; and products that are used to support healing of chronic wounds, as well as advanced rehabilitation devices designed to help patients regain leg or hand function. It serves physicians spanning the orthopedic continuum, including sports medicine, total joint reconstruction, hand and upper extremities, foot and ankle, podiatric surgery, trauma, spine, and neurosurgery in the physician's office or clinic, ambulatory surgical centers, or in the hospital setting. The company was founded in 2011 and is headquartered in Durham, North Carolina.

At a Glance

Live Snapshot
Market Cap$579.25M
EPS0.3400
P/E Ratio25.15
Earnings Date08/05/2026
3Y+11.0%
5Y+77.0%
10Y+107.0%
3Y-114.0%
5Y+39.0%
10Y-227.0%
3Y-646.0%
5Y+3.0%
10Y+390.0%
Bioventus Inc.

Bioventus Inc. Profit Bridge

BVS ยท NASDAQ
Revenue568.09M
Cost of Goods Sold (185.66M)
Gross Profit382.43M
Operating Expenses (323.88M)
Operating Income58.55M
Interest Expense (26.49M)
Other Income/Expense-32.84M
Pretax Income25.71M
Income Tax (-1.56M)
Net Income22.73M
Net Income
22.73M

Profitability Analysis

Gross Margin

67.3%

Exceptional pricing power and cost management. The company retains over half of revenue after direct costs.

Operating Margin

10.3%

Acceptable margins but limited operational leverage. Operating expense control is important.

Net Profit Margin

4.0%

Minimal profitability after all expenses. Limited financial flexibility for reinvestment or shareholder returns.

Effective Tax Rate

-6.1%

Below-average tax rate suggests effective tax planning, favorable jurisdictions, or tax credits.

Profitability Insight

High margin compression: Large gap between gross and net margins suggests operational inefficiencies or heavy debt burden. Focus on expense management and deleveraging.

Bioventus Inc. Income Statement

BVS โ€ข NASDAQ

Bioventus Inc. Income StatementDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016Dec 2015Dec 2014Dec 2013
REVENUE
568.1M
573.3M
512.3M
512.1M
430.9M
321.2M
340.1M
319.2M
292.1M
274.5M
253.7M
242.9M
232.4M
GROSS PROFIT
(185.7M)
(185.1M)
(184.2M)
(181M)
(128.2M)
(87.6M)
(90.9M)
(84.2M)
(92.1M)
(91.4M)
(74.3M)
(74.6M)
(71.4M)
382.4M
388.2M
328.2M
331.1M
302.7M
233.5M
249.2M
235M
200M
183.1M
179.3M
168.3M
161M
OPERATING INCOME
(323.9M)
(400.2M)
(409.9M)
(498.3M)
(290.6M)
(212.3M)
(218M)
(209.5M)
(172.9M)
(168.2M)
(173.8M)
(165.5M)
(169.1M)
(314M)
(327.1M)
(303.9M)
(332.1M)
(254.3M)
(193.1M)
(198.5M)
(191.7M)
(164.8M)
(160.3M)
(148.4M)
(147.1M)
(150.4M)
(12.1M)
(13.6M)
(13.4M)
(23.9M)
(19M)
(11.2M)
(11.1M)
(8.1M)
(8.1M)
(7.9M)
(14.7M)
(9.5M)
(10.9M)
58.5M
-12M
-81.7M
-167.2M
12.1M
21.2M
31.2M
25.5M
27M
14.9M
-16.6M
20K
-8.1M
PRE-TAX INCOME
(26.5M)
(38.8M)
(40.7M)
(12M)
(1.1M)
(9.8M)
(21.6M)
(19.2M)
(18.9M)
(15.9M)
(14.2M)
(12M)
(11.5M)
-26.5M
-38.8M
-40.7M
-12M
-1.1M
-9.8M
-21.6M
-19.2M
0.0
0.0
-14.2M
-12M
-11.5M
-2.3M
(59.5M)
(92.6M)
(142.3M)
(17.4M)
(8M)
(8.5M)
(9.7M)
(0.0)
(0.0)
(10.6M)
(9M)
(7.8M)
-32.8M
-37.1M
-39.4M
-21.8M
-2.6M
-5.3M
-21.5M
-19.4M
-18.4M
-20.5M
-15.4M
-11.4M
-12.2M
25.7M
-49.1M
-121.1M
-189M
9.5M
15.9M
9.7M
6.1M
8.7M
-5.7M
-32M
-11.4M
-20.2M
NET INCOME
-1.6M
-5.3M
(85K)
-44.4M
-2M
(1.2M)
(1.6M)
(1.7M)
-785K
(1.1M)
(2.1M)
(1.5M)
(2.1M)
22.7M
-33.5M
-156.2M
-158.7M
19.4M
16.4M
6.9M
-12.2M
-1.6M
-18M
-34.1M
-12.9M
-22.4M

SEC Filings

BVS - Filing history and reports

Filing TypeFiling DatePeriod EndingFiscal YearActions
8-K

8-K 2026

N/A

May 21, 2026
May 21, 2026
2026
10-Q

10-Q 2026 Q1

Q1

May 06, 2026
March 28, 2026
2026
8-K

8-K 2026

N/A

May 06, 2026
May 06, 2026
2026
DEF 14A

DEF 14A 2025

N/A

April 22, 2026
December 31, 2025
2025
10-K

10-K 2025 FY

FY

March 05, 2026
December 31, 2025
2025
8-K

8-K 2026

N/A

March 05, 2026
March 05, 2026
2026
8-K

8-K 2025

N/A

November 17, 2025
November 14, 2025
2025
10-Q

10-Q 2025 Q3

Q3

November 04, 2025
September 27, 2025
2025
8-K

8-K 2025

N/A

November 04, 2025
November 04, 2025
2025
8-K

8-K 2025

N/A

August 06, 2025
August 06, 2025
2025
Showing 1 to 10 of 108 filings